Lung Cancer Diagnostics Market

Market Snapshot:

A newly published report by Fact.MR estimates the global lung cancer diagnostics market revenue to reach US$ 4 Bn by 2031, representing a 2x increase from 2020. Augmented development of lung cancer-specific biomarkers is propelling demand for the lung cancer diagnostics over the forecast period. Revenue from CA tests will account for US$ 1 Bn by 2031-end.

Amongst the many factors credited to the expanding demand for lung cancer diagnostics is the mounting figure of cancer cases with around 12% annual growth.  Moreover, contrary to the backdrop of the emergent picture of disease severity, there is a growing focus shed on early detection, diagnosis, and supportive treatment. 

Key Points Covered in Lung Cancer Diagnostics Industry Survey:

• Market Estimates and Forecasts 2016-2031
• Key drivers and restraints shaping market growth
• Segment-wise, Country-wise, and Region-wise Analysis
• Competition Mapping and Benchmarking
• Market Share Analysis
• Key Product Innovations and Regulatory Climate
• COVID-19 Impact on lung cancer diagnostics and how to navigate
• Recommendation on key winning strategies.

Lung Cancer Diagnostics Marketplace Analysis from 2016-2020 Vs Future Outlook for 2021 to 2031

The market for lung cancer diagnostics was estimated at US$ 1.6 Bn in 2016 with an expansion rate of approximately 6% until 2020. Growing number of private diagnostic laboratories spurred demand in the historical period.

Conferring to a Cancer report by WHO, the most frequently diagnosed cancer and a leading cause of death is lung cancer (11.6% of all cases) followed by female breast (11.6%) and colorectal cancers (10.2%).

It is predicted that global demand for lung cancer diagnostics will cultivate at a CAGR of around 7% and prospective to record market value at US$ 4 Bn over the forecast period 2021-2031.

Which are Some Lucrative Growth Opportunities for Lung Cancer Diagnostics Technology?

Increasing spending on cancer treatment research is offering lucrative opportunities for the growth of the early-stage lung cancer diagnostics market. Majority of lung cancer patients are diagnosed at advanced stages which cannot be cured by surgery or other therapeutic modalities.

Additionally, accessibility of private and government funds for R&D to develop better tumour diagnostic tools, organizations such as NCI are supporting diagnostic developments to reduce the cost of screening open new doors for the manufacturers to expand the market size. However, for cancer relief CA tests will continue to be the most lucrative tests for lung cancer diagnostics in the market.

What Are Some Key Trends in the Market?

Adoption of advanced multimodal diagnostic approaches is heavily influencing lung cancer diagnosis. For instance, liquid biopsy and breath analysis developments are the most promising and advanced technologies for the detection of biomarkers associated with lung cancer.

Wearable devices and AI are two niche areas that require development and standardization for commercialization. The upcoming technology based on nano-systems includes robots, fibres, and particles for sensitive detection of lung cancer.

Soon, nanotechnology-based theranostics, aptamers, and MIPs will befall in the early-stage diagnosis of lung cancer. These trends are expected to boost the demand for lung cancer diagnostics attributed to their laid-back usage and comparatively reduced cost.

Challenges to Lung Cancer Diagnostics Market Growth

Recently, expectations have been rising that overall survival rates for lung cancer could increase with the recent advent of various biological agents for the treatment of lung cancer.

However, the treatment costs for new biologics are very high lung cancer patients have approximately 4 times higher monthly medical expenditure compared to matched controls during their lifetime. Leading to this, increased adoption of refurbished machines for screening of lung cancer is witnessed.

Along with this, the treatment costs for new biologics are very high which hinders the market growth and affects the affordability of expensive diagnostics for cancer detection and screening.

Country-wise Analysis:

Why is the U.S Experiencing High Demand for Lung Cancer Diagnostics?

The U.S. accounted for over 27% of the global market size in 2020 which is prospective to foster demand in the forthcoming decade. The lung cancer diagnostics market in the U.S. is estimated to surpass US$ 900 Mn by the end of 2031.

Over the last 10 years, many researchers with American Cancer Society (ACS) grants have contributed to that growth. For instance, ACS-funded researchers across the US have developed ways to quickly analyse the large amounts of data that result from gene sequencing, identify mutations in lung cancer genes, and helped find new treatments for lung cancer patients.

Why is Lung Cancer Diagnostics Market Flourishing in China?

China is likely to contribute around 8% CAGR in the market for lung cancer diagnostics. Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China with a 37% oncology market representation of all lung cancer.

It is estimated that the Chinese NSCLC therapy market to experience robust growth in the coming years ahead. The biggest driver of market sales growth will be the continued uptake and anticipated approvals of immune checkpoint inhibitors.

Category-wise insights:

How are Cancer Research Institutes Influencing Demand for Lung cancer diagnostics?

Latest research and developments in cancer diagnostics stimulate the demand for the lung cancer diagnostics market. For instance, In May 2021 the Food and Drug Administration (FDA) granted accelerated approval to the first KRAS-blocking drug, called sotorasib (Lumakras) which is a breakthrough in the treatment of lethal lung cancer.

Additionally, recent progressions in cancer diagnostics have reduced the global mortality rate. As per Fact.MR, the segment is expected to grow at around 6% CAGR.

Why Hospital-Based Labs Remain Prominent End Users?

Hospital-associated labs will remain the most lucrative end-users of lung cancer diagnostics in the global market, with revenues estimated to reach nearly US$ 1.6 Bn by 2031-end.

Increasing number of patients visiting hospitals, the rising number of in-house diagnostic procedures performed in hospitals, and cumulative awareness regarding early diagnosis are the major driving factor for this market.

Competitive Landscape

Prominent players are embracing innovative approaches such as ground-breaking marketing tactics, technological advances for cancer screening, mergers, and acquisitions.   

• In March 2021, Next-generation sequencing (NGS)-based precision oncology provider Geneseeq Technology Inc. collaborated with Illumina, Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer, using Illumina's NextSeq™ 550Dx sequencing platform. 
• In Jan 2017, Abbott Laboratories completed largest the acquisition of St.Jude Medical for US$ 25 Bn. Together, the company will compete in nearly every area of the $30 billion cardiovascular markets and hold the No. 1 or 2 positions across large and high-growth cardiovascular device markets

Scope of the report:

Segmentation:

Test Type

• CA Test for Lung Cancer Diagnostics
• HER2 Tests for Lung Cancer Diagnostics
• ALK Tests for Lung Cancer Diagnostics
• Angiogenesis Inhibitor for Lung Cancer Diagnostics
• EGFR Mutation Tests for Lung Cancer Diagnostics
• KRAS Mutation Tests for Lung Cancer Diagnostics
• Others

End-User

• Lung Cancer Diagnostics  for Hospital Associated Labs
• Lung Cancer Diagnostics for Independent Diagnostic Laboratories
• Lung Cancer Diagnostics for Cancer Research Institutes
• Others

Indication

• Non-Small-cell Lung Cancer Diagnostics
• Small-cell Lung Cancer Diagnostics

Lung Cancer Diagnostics Market- Scope of Report

A recent study by Fact.MR on the lung cancer diagnostics market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with the manufacturing of the lung cancer diagnostics market.

The study also provides the dynamics responsible for influencing the future status of the lung cancer diagnostics market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the lung cancer diagnostics market, along with their product portfolios, enhances the reliability of this comprehensive research study.

Report Summary

The study offers a comprehensive analysis of diverse features, including production capacities, demand, product developments, revenue generation, and sales of the lung cancer diagnostics market across the globe.

A comprehensive estimate of the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the lung cancer diagnostics market during the forecast period. Price point comparison by region with the global average price is also considered in the study.

Key Questions Answered in Report

• Which are the most lucrative lung cancer diagnostics markets?
• Which factors will impact the growth of lung cancer diagnostics?
• How will changing trends impact the strategies of market players?
• How can market players capture the low-hanging opportunities across regions?
• Which companies are leading the lung cancer diagnostics industry?
• What are the winning strategies of stakeholders in the market?

Analysis of Market Size Evaluation

The market has been analyzed for each segment in terms of volume (‘000 Units) and value (US$ Mn).

Estimates at global and regional levels for the reinforced thermoplastic market are available in terms of “US$ Mn” for value and in “‘000 Units” for volume. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report. Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global lung cancer diagnostics market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which has helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the lung cancer diagnostics market during the forecast period.

Country-specific valuation on demand for lung cancer diagnostics market has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition Analysis

The report sheds light on leading manufacturers of the lung cancer diagnostics market, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in producing lung cancer medicines have been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permit report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which includes essentials such as product portfolios and key strategies, along with an all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the lung cancer diagnostics market domain. 

Research Methodology

In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the lung cancer diagnostics market industry, and reach conclusions on the future growth parameters. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the drawn conclusions.

Secondary resources referred to by analysts during the preparation of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of the research report as a primary resource.